Patents by Inventor Jide Tian
Jide Tian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11872200Abstract: In certain embodiments methods are provided for the therapeutic or prophylactic amelioration of one or more symptoms or disorders associated with metabolic syndrome. In various embodiments the methods involve administering to a subject in need thereof, a GABA receptor agonist, in an amount sufficient to ameliorate said one or more symptoms. In certain embodiments methods are provided for the prophylaxis or treatment of type I diabetes and related pathologies that involve the use of GABA or GABA agonists in combination with certain other compounds (e.g., one more antigens (e.g., GAD) that have a therapeutic effect in type I diabetes and/or an anti-CD3 antibody, an anti-CD20 antibody, exendin-4, and/or or a pro-insulin therapeutic).Type: GrantFiled: March 22, 2021Date of Patent: January 16, 2024Assignee: The Regents of the University of CaliforniaInventors: Daniel L Kaufman, Jide Tian
-
Publication number: 20230381125Abstract: Use of GABA-receptor agonists, either alone or with one or more positive PAMs, anti-inflammatory compounds, and/or antiviral treatments, e.g., one that limits viral replication or impacts other viral functions, to ameliorate, treat, and/or prevent illness arising from infections, including bacterial, fungal, and/or viral infections, inpatients, including to: ameliorate infection-related medical conditions; ameliorate and/or prevent coronavirus-related medical conditions; inhibit viral replication; inhibit corona virus replication; ameliorate and/or treat coronavirus-induced medical conditions; ameliorate and/or prevent respiratory virus-related medical conditions; and ameliorate and/or modulate dysregulated immune responses.Type: ApplicationFiled: September 24, 2021Publication date: November 30, 2023Applicant: The Regents of the University of CaliforniaInventors: Daniel L. KAUFMAN, Jide TIAN
-
Publication number: 20210353751Abstract: The present application relates to a combination therapy for treatment of inflammatory diseases comprising an immunomodulator compound and a GABA-receptor agonist in an amount effective to reduce inflammation and ameliorate disease. In certain embodiments, the present application relates to treatment of T1D by administering an immunomodulator compound and a GABA-receptor agonist in an amount effective to prevent, reduce, and/or treat hyperglycemia in the human or animal subject. In certain embodiments, the immunomodulator compound and GABA-receptor agonist are administered in an amount effective to control autoimmune responses and safely increase ?-cell mass and function in the context of established ?-cell autoimmunity.Type: ApplicationFiled: October 18, 2019Publication date: November 18, 2021Applicant: The Regents of The University of CaliforniaInventors: Daniel Kaufman, Jide Tian
-
Publication number: 20210205248Abstract: In certain embodiments methods are provided for the therapeutic or prophylactic amelioration of one or more symptoms or disorders associated with metabolic syndrome. In various embodiments the methods involve administering to a subject in need thereof, a GABA receptor agonist, in an amount sufficient to ameliorate said one or more symptoms. In certain embodiments methods are provided for the prophylaxis or treatment of type I diabetes and related pathologies that involve the use of GABA or GABA agonists in combination with certain other compounds (e.g., one more antigens (e.g., GAD) that have a therapeutic effect in type I diabetes and/or an anti-CD3 antibody, an anti-CD20 antibody, exendin-4, and/or or a pro-insulin therapeutic).Type: ApplicationFiled: March 22, 2021Publication date: July 8, 2021Applicant: The Regents of the University of CaliforniaInventors: Daniel L. Kaufman, Jide Tian
-
Patent number: 10952980Abstract: In certain embodiments methods are provided for the therapeutic or prophylactic amelioration of one or more symptoms or disorders associated with metabolic syndrome. In various embodiments the methods involve administering to a subject in need thereof, a GABA receptor agonist, in an amount sufficient to ameliorate said one or more symptoms. In certain embodiments methods are provided for the prophylaxis or treatment of type I diabetes and related pathologies that involve the use of GABA or GABA agonists in combination with certain other compounds (e.g., one more antigens (e.g., GAD) that have a therapeutic effect in type I diabetes and/or an anti-CD3 antibody, an anti-CD20 antibody, exendin-4, and/or or a pro-insulin therapeutic).Type: GrantFiled: October 4, 2019Date of Patent: March 23, 2021Assignee: The Regents of The University of CaliforniaInventors: Daniel L. Kaufman, Jide Tian
-
Publication number: 20200138830Abstract: Embodiments methods of reducing an inflammatory immune response (e.g., inhibiting a Th1 response) and/or promoting a regulatory immune response (e.g., enhancing Treg(s)) in a mammal are provided where the method methods involve administering to the mammal a GABAA receptor positive allosteric modulator (PAM) in an amount sufficient to reduce an inflammatory immune response and/or to promote a regulatory immune response said mammal. In certain embodiments the PAM is administered in conjunction with a GABA receptor activating ligand (e.g., GABA).Type: ApplicationFiled: June 20, 2018Publication date: May 7, 2020Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Daniel Kaufman, Jide Tian
-
Publication number: 20200030272Abstract: In certain embodiments methods are provided for the therapeutic or prophylactic amelioration of one or more symptoms or disorders associated with metabolic syndrome. In various embodiments the methods involve administering to a subject in need thereof, a GABA receptor agonist, in an amount sufficient to ameliorate said one or more symptoms. In certain embodiments methods are provided for the prophylaxis or treatment of type I diabetes and related pathologies that involve the use of GABA or GABA agonists in combination with certain other compounds (e.g., one more antigens (e.g., GAD) that have a therapeutic effect in type I diabetes and/or an anti-CD3 antibody, an anti-CD20 antibody, exendin-4, and/or or a pro-insulin therapeutic).Type: ApplicationFiled: October 4, 2019Publication date: January 30, 2020Applicant: The Regents of the University of CaliforniaInventors: Daniel L. Kaufman, Jide Tian
-
Patent number: 10434078Abstract: In certain embodiments methods are provided for the therapeutic or prophylactic amelioration of one or more symptoms or disorders associated with metabolic syndrome. In various embodiments the methods involve administering to a subject in need thereof, a GABA receptor agonist, in an amount sufficient to ameliorate said one or more symptoms. In certain embodiments methods are provided for the prophylaxis or treatment of type I diabetes and related pathologies that involve the use of GABA or GABA agonists in combination with certain other compounds (e.g., one more antigens (e.g., GAD) that have a therapeutic effect in type I diabetes and/or an anti-CD3 antibody, an anti-CD20 antibody, exendin-4, and/or or a pro-insulin therapeutic).Type: GrantFiled: October 17, 2017Date of Patent: October 8, 2019Assignee: The Regents of The University of CaliforniaInventors: Daniel L. Kaufman, Jide Tian
-
Publication number: 20180235916Abstract: In certain embodiments methods of promoting the replication, and/or survival, and/or function of beta cells in mammal are provided where the methods comprise administering to a mammal a GABA receptor activating ligand in conjunction with a GABAA receptor positive allosteric modulator (PAM) where the GABA receptor activating ligand is used at a lower dosage than would be used to achieve the same effect on beta cell replication, and/or survival, and/or function when used alone and/or said positive allosteric modulator is used at a subtherapeutic dosage.Type: ApplicationFiled: October 12, 2016Publication date: August 23, 2018Inventors: Daniel L. Kaufman, Jide Tian
-
Publication number: 20180193295Abstract: In certain embodiments methods are provided for the therapeutic or prophylactic amelioration of one or more symptoms or disorders associated with metabolic syndrome. In various embodiments the methods involve administering to a subject in need thereof, a GABA receptor agonist, in an amount sufficient to ameliorate said one or more symptoms. In certain embodiments methods are provided for the prophylaxis or treatment of type I diabetes and related pathologies that involve the use of GABA or GABA agonists in combination with certain other compounds (e.g., one more antigens (e.g., GAD) that have a therapeutic effect in type I diabetes and/or an anti-CD3 antibody, an anti-CD20 antibody, exendin-4, and/or or a pro-insulin therapeutic).Type: ApplicationFiled: October 17, 2017Publication date: July 12, 2018Inventors: Daniel L. Kaufman, Jide Tian
-
Patent number: 9820955Abstract: In certain embodiments methods are provided for the therapeutic or prophylactic amelioration of one or more symptoms or disorders associated with metabolic syndrome. In various embodiments the methods involve administering to a subject in need thereof, a GABA receptor agonist, in an amount sufficient to ameliorate said one or more symptoms. In certain embodiments methods are provided for the prophylaxis or treatment of type I diabetes and related pathologies that involve the use of GABA or GABA agonists in combination with certain other compounds (e.g., one more antigens (e.g., GAD) that have a therapeutic effect in type I diabetes and/or an anti-CD3 antibody, an anti-CD20 antibody, exendin-4, and/or or a pro-insulin therapeutic).Type: GrantFiled: June 26, 2015Date of Patent: November 21, 2017Assignee: The Regents of the University of CaliforniaInventors: Daniel Kaufman, Jide Tian
-
Publication number: 20160081956Abstract: In certain embodiments methods are provided for the therapeutic or prophylactic amelioration of one or more symptoms or disorders associated with metabolic syndrome. In various embodiments the methods involve administering to a subject in need thereof, a GABA receptor agonist, in an amount sufficient to ameliorate said one or more symptoms. In certain embodiments methods are provided for the prophylaxis or treatment of type I diabetes and related pathologies that involve the use of GABA or GABA agonists in combination with certain other compounds (e.g., one more antigens (e.g., GAD) that have a therapeutic effect in type I diabetes and/or an anti-CD3 antibody, an anti-CD20 antibody, exendin-4, and/or or a pro-insulin therapeutic).Type: ApplicationFiled: June 26, 2015Publication date: March 24, 2016Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Daniel Kaufman, Jide Tian
-
Patent number: 9089531Abstract: In certain embodiments methods are provided for the therapeutic or prophylactic amelioration of one or more symptoms or disorders associated with metabolic syndrome. In various embodiments the methods involve administering to a subject in need thereof, a GABA receptor agonist, in an amount sufficient to ameliorate said one or more symptoms. In certain embodiments methods are provided for the prophylaxis or treatment of type I diabetes and related pathologies that involve the use of GABA or GABA agonists in combination with certain other compounds (e.g., one more antigens (e.g., GAD) that have a therapeutic effect in type I diabetes and/or an anti-CD3 antibody, an anti-CD20 antibody, exendin-4, and/or or a pro-insulin therapeutic).Type: GrantFiled: September 28, 2011Date of Patent: July 28, 2015Assignee: The Regents of the University of CaliforniaInventors: Daniel Kaufman, Jide Tian
-
Publication number: 20130251671Abstract: In certain embodiments methods are provided for the therapeutic or prophylactic amelioration of one or more symptoms or disorders associated with metabolic syndrome. In various embodiments the methods involve administering to a subject in need thereof, a GABA receptor agonist, in an amount sufficient to ameliorate said one or more symptoms. In certain embodiments methods are provided for the prophylaxis or treatment of type I diabetes and related pathologies that involve the use of GABA or GABA agonists in combination with certain other compounds (e.g., one more antigens (e.g., GAD) that have a therapeutic effect in type I diabetes and/or an anti-CD3 antibody, an anti-CD20 antibody, exendin-4, and/or or a pro-insulin therapeutic).Type: ApplicationFiled: September 28, 2011Publication date: September 26, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Daniel Kaufman, Jide Tian
-
Publication number: 20050202032Abstract: Disclosed are methods for identifying antigens, termed neglected target tissue antigens, that do not become involved as targets of an abnormal immune response (such as allergy or autoimmunity or more generally inflammation); also disclosed are methods of using NTTAs for inducing regulatory responses and thereby abating abnormal inflammatory immune responses.Type: ApplicationFiled: January 9, 2004Publication date: September 15, 2005Applicant: The Regents of the University of CaliforniaInventors: Daniel Kaufman, Jide Tian, Angelica Olcott
-
Publication number: 20030017509Abstract: Methods for detecting the status of an insulin-dependent diabetes mellitus (IDDM)-associated autoimmune response in a mammal are provided. Specifically, the ratio of the frequency of T helper 1 cells to T helper 2 cells specific for a pancreatic &bgr;-cell associated antigen is indicative of the status of the autoimmune response. The methods may be employed prior to the onset of the clinical symptoms of the disease, thereby allowing identification of those at risk for developing clinical symptoms of IDDM, or subsequent to pancreatic tissue transplantation, for example, to measure the efficacy of treatment directed to enhancing the lifetime of the tissue transplant. Methods for prolonging the survival of tissue transplants are also provided. Specifically, a tissue-associated antigen is administered to the mammal which serves to shift the pathogenic Th1 response associated with pathological immunity toward a protective Th2 response.Type: ApplicationFiled: December 12, 2000Publication date: January 23, 2003Applicant: The Regents of The University of California.Inventors: Daniel L. Kaufman, Jide Tian
-
Patent number: 6350769Abstract: The present invention provides new methods for modulating immune responses. The methods are based on the discovery that GABAA receptors are present on peripheral lymphocytes. Thus, GABA agonists and antagonists can be used to modulate immune responses.Type: GrantFiled: February 24, 2000Date of Patent: February 26, 2002Assignee: The Regents of the University of CaliforniaInventors: Daniel L. Kaufman, Jide Tian
-
Patent number: 6207159Abstract: Methods for detecting the status of an insulin-dependent diabetes mellitus (IDDM)-associated autoimmune response in a mammal are provided. Specifically, the ratio of the frequency of T helper 1 cells to T helper 2 cells specific for a pancreatic &bgr;-cell associated antigen is indicative of the status of the autoimmune response. The methods may be employed prior to the onset of the clinical symptoms of the disease, thereby allowing identification of those at risk for developing clinical symptoms of IDDM, or subsequent to pancreatic tissue transplantation, for example, to measure the efficacy of treatment directed to enhancing the lifetime of the tissue transplant. Methods for prolonging the survival of tissue transplants are also provided. Specifically, a tissue-associated antigen is administered to the mammal which serves to shift the pathogenic Th1 response associated with pathological immunity toward a protective Th2 response.Type: GrantFiled: July 21, 1998Date of Patent: March 27, 2001Assignee: The Regents of the University of CaliforniaInventors: Daniel L. Kaufman, Jide Tian
-
Patent number: 6022697Abstract: Methods for detecting the status of an insulin-dependent diabetes mellitus (IDDM)-associated autoimmune response in a mammal are provided. Specifically, the ratio of the frequency of T helper 1 cells to T helper 2 cells specific for a pancreatic .beta.-cell associated antigen is indicative of the status of the autoimmune response. The methods may be employed prior to the onset of the clinical symptoms of the disease, thereby allowing identification of those at risk for developing clinical symptoms of IDDM, or subsequent to pancreatic tissue transplantation, for example, to measure the efficacy of treatment directed to enhancing the lifetime of the tissue transplant. Methods for prolonging the survival of tissue transplants are also provided. Specifically, a tissue-associated antigen is administered to the mammal which serves to shift the pathogenic Th1 response associated with pathological immunity toward a protective Th2 response.Type: GrantFiled: July 9, 1997Date of Patent: February 8, 2000Assignee: The Regents of the University of CaliforniaInventors: Daniel L. Kaufman, Jide Tian